Illumina, Inc. announced today that Mark Van Oene has been named Chief Commercial Officer. Van Oene was previously Illumina’s Senior Vice President of the Americas region and subsequently named interim Chief Commercial Officer in late 2016.
“Mark is a great leader for our commercial organization, possessing deep genomics expertise and over a decade of experience building and running strong sales and marketing teams,” said Francis deSouza, Illumina President and Chief Executive Officer. “As interim Chief Commercial Officer Mark has guided Illumina through two strong quarters, including the launch of NovaSeq, and laid the foundation for our future growth. I am excited to continue to work closely with Mark to expand our commercial capability as we grow in research and clinical markets around the world.”
Van Oene joined Illumina in 2006 as Regional Account Manager for Canada. In 2008, Van Oene was promoted to Senior Director of Sales for the Americas. Four years later, he was promoted to Vice President with responsibility for global sales. From 2012 through 2014, Van Oene led the team to grow revenues from $1.06B to $1.42B. In early 2014, Van Oene was named the General Manager for the Americas region, advancing to Senior Vice President in April 2016. During that time, the Americas compound annual growth rate exceeded 20%.
As Chief Commercial Officer, Van Oene will be responsible for world-wide sales, services and marketing at Illumina. He will report to President and CEO, Francis deSouza.
Van Oene earned a Bachelor of Science degree in Biochemistry from Western University in London, Ontario, Canada.
Source: Illumina
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
